Insulin Lispro Sanofi

Insulin lispro, the active ingredient in Insulin Lispro Sanofi, is an insulin analog presented as a clear solution for injection for subcutaneous use. It is used to lower blood glucose levels in patients with type 1 or type 2 diabetes mellitus, providing rapid‑acting insulin coverage around meals.

GNH USA supplies Insulin Lispro Sanofi as a licensed, Good Distribution Practice‑compliant international pharmaceutical supplier, delivering the product to hospitals, pharmacies and clinics worldwide while ensuring quality and regulatory compliance across markets.

Insulin lispro is a rapid‑acting insulin analog that acts on post‑prandial glucose control in diabetes mellitus. - Type 1 diabetes mellitus: provides rapid‑acting insulin to control post‑prandial glucose spikes. - Type 2 diabetes mellitus: used as part of basal‑bolus regimens to improve overall glycemic control.

Common side effects of rapid‑acting insulin analogues include:

Common Side Effects: - Hypoglycemia: low blood sugar episodes, especially if meals are missed or delayed. - Injection site reactions: redness, swelling, or itching at the injection site. - Weight gain: modest increase due to improved glucose utilization. - Lipodystrophy: localized fat tissue changes from repeated injections. - Nausea or headache: occasional transient symptoms.

Serious or Rare Side Effects: - Severe hypoglycemia: may cause seizures, loss of consciousness, or require emergency treatment. - Allergic reactions: rash, urticaria, or anaphylaxis in rare cases. - Edema: swelling of extremities due to fluid retention. - Hypokalemia: low potassium levels, particularly with high insulin doses. - Acute insulin resistance: sudden loss of insulin effectiveness.

When using Insulin Lispro Sanofi, consider the following precautions: - Dose adjustment: regularly monitor blood glucose and adjust dose accordingly. - Renal impairment: may require dose modification due to altered insulin clearance. - Pregnancy: use only if the potential benefit justifies the potential risk to the fetus. - Hypoglycemia risk: educate patients on recognizing and treating low blood sugar promptly. - Drug interactions: avoid concurrent use with other rapid‑acting insulins without medical supervision. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake the vial.

Insulin lispro may interact with several medications that affect glucose metabolism.

Major Interactions (Avoid): - Concurrent use of other rapid‑acting insulins: increased risk of severe hypoglycemia. - Beta‑blockers: may mask typical hypoglycemia symptoms such as tachycardia.

Moderate Interactions (Monitor Closely): - Sulfonylureas or meglitinides: additive glucose‑lowering effect, monitor for hypoglycemia. - ACE inhibitors or ARBs: may potentiate insulin’s glucose‑lowering action. - Thiazide diuretics: can raise blood glucose levels, requiring dose adjustment. - Corticosteroids: may increase insulin requirements due to hyperglycemic effect.